Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0MPSKX
ADC Name
2-DG/aV-siCPT1C
Synonyms
2-DG/aV siCPT1C
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Glioblastoma [ICD11:2A00]
Investigative
Antibody Name
Ramucirumab
  Antibody Info 
Antigen Name
Vascular endothelial growth factor receptor 2 (KDR)
  Antigen Info 
Payload Name
siCPT1C
  Payload Info 
Therapeutic Target
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)
  Target Info 
Linker Name
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
  Linker Info 
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1.1
ug/mL
U-87MG cells
Glioblastoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.10 ug/mL Positive VEGFR2 expression (VEGFR2 +++/++)
Method Description
The Cell Counting Kit-8 (CCK8) method was used to detect the effect of nanocapsules on cell viability. The cultured U87 and HA1800 cells were placed in a 96-well plate at a density of 5 x 103 cells/well. After 24 h of culture, PBS, 2-DG/aV-siCPT1C NC were added.
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
References
Ref 1 Cascade-Responsive 2-DG Nanocapsules Encapsulate aV-siCPT1C Conjugates to Inhibit Glioblastoma through Multiple Inhibition of Energy Metabolism. ACS Appl Mater Interfaces. 2023 Mar 1;15(8):10356-10370. doi: 10.1021/acsami.2c19285. Epub 2023 Feb 14.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.